 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C19H29N5O2 |
| Molar mass | 359.474 g·mol−1 |
| 3D model (JSmol) | |
| |
Lavoltidine (INN,[1]USAN,BAN; previously known asloxtidine; development codeAH-23,844) is a highlypotent andselectiveH2 receptorantagonist which was under development by Glaxo Wellcome (nowGlaxoSmithKline)[2] as a treatment forgastroesophageal reflux disease but was discontinued due to the discovery that it producedgastric carcinoid tumors in rodents.[3][4]
